Cell and Gene Therapy Market Size, Share & Trends Analysis Report By Product (Cell Therapy, Gene Therapy, Others), By Applications (Oncology, Rare Diseases, Cardiovascular Diseases, Others), By End Use, By Region, and Segment Forecasts - 2035

CELL AND GENE THERAPY MARKET REPORT OVERVIEW

The cell and gene therapy market size is expected to grow from USD 22027.02 million in 2025 to USD 24753.96 million in 2026 and is forecast to reach USD 35132.71 million by 2035 at 12.38% CAGR over 2026-2035.

It is expected that the interest of many people in finding solutions to treat a variety of chronic and genetic diseases will likely enhance the market for cell and gene therapies. These have paved the way for an evolution of events that made possible therapies that could alter the causes of the diseases at the genetic and the cellular level and provide a cure rather than just symptom management. The demand for cell and gene therapies is likely to enhance with the rising occurrences of cancer, rare genetic disorders, and cardiovascular diseases. Therapies that involve CAR-T cell therapy and gene editing technologies, such as that by CRISPR, are gaining wide acceptance due to their potential for personalized treatment with better patient-based outcomes. Growing investments in research and regulatory support will likely boost this market further.

The United States is the global leader in the cell and gene therapy market, supported by advanced biotechnology research, strong clinical trial activity, and an established regulatory framework. More than 4,000 active cell and gene therapy clinical trials are underway globally, with the United States accounting for the largest share. The country has over 3,000 biotechnology companies and more than 190 FDA-approved regenerative medicine designations supporting innovation in rare diseases, oncology, and genetic disorders. Expanding manufacturing capacity, increasing adoption of CAR-T therapies, and advances in viral vector production continue to strengthen the U.S. market, while investments in automated cell processing and gene-editing technologies accelerate commercialization.

• • 

    Download Free sample to learn more about this report.

CELL AND GENE THERAPY MARKET KEY FINDINGS

• Market Size and Growth: The Cell and Gene Therapy Market size was USD 19,600.47 million in 2024, is projected to grow to USD 21,928.93 million by 2025 and exceed USD 27,818.49 million by 2033, with a CAGR of 12.38% from 2025–2033.

• Key Market Driver: Rising approvals are fueling momentum—over 30 cell and gene therapies have received FDA approval as of 2024, a significant leap from fewer than 10 a decade ago.

• Major Market Restraint: Manufacturing bottlenecks remain a headache—only 12% of therapy developers report having end-to-end in-house production capabilities.

• Emerging Trends: Allogeneic therapies are gaining traction, with over 40% of pipeline candidates now exploring off-the-shelf alternatives to autologous treatments.

• Regional Leadership: North America leads the charge, driven by strong R&D and regulatory frameworks, contributing to over 45% of global clinical trials in this space.

• Competitive Landscape: The market is crowded but dynamic—more than 1,200 active players are working on therapies globally, ranging from startups to big pharma giants like Novartis and Gilead.

• Market Segmentation: Oncology dominates with over 50% of pipeline therapies targeting cancers such as lymphoma, leukemia, and glioblastoma.

• Recent Development: In 2023, the FDA approved Lyfgenia (lovotibeglogene autotemcel) by bluebird bio for sickle cell disease—marking one of the first gene therapies using lentiviral vectors in this indication.

COVID-19 IMPACT: MARKET GROWTH ACCELERATED BY INCREASED FOCUS ON BIOTECHNOLOGY

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

It encourages market growth as the focus on biotechnology is increased because of Covid-19. The pandemic has created chaos in the whole world and immensely influences the cell and gene therapy market by providing increased interested in advanced medical treatments for the same. Besides, to some extent, the pandemic was able to prove that high-level biotechnological solutions are among the tools with which humanity possibly has a chance to solve some global health Challenges. This has subsequently fueled research and development in the area of cell and gene therapy. On the other hand, although a few clinical trial and their relevant supply chains were initially affected, the market soon recovered, and many companies went on to develop conditions for COVID-19 treatments. Based on these factors, the investment and attention increases experienced by the biotechnology market during the pandemic have drastically accelerated its growth trajectory, leaving it in a very good place for future expansion during the post-pandemic times.

LATEST TREND

"Advancements in Gene Editing Technologies to Drive Market Growth"

These are technologies that can be quite helpful in the manipulation of genetic material within cells with a very particular level of precision that is required to provide therapies against a large number of diseases by correcting the genetic defect at its root, wherever possible. Gene editing integrated into therapeutic applications is likely to bring about a revolutionary step in treating genetic disorders, cancers, and other chronic conditions. This could be a probable driver to new products and further growth in this space, with more and more such studies and clinical experiments.

• • 

    Download Free sample to learn more about this report.

CELL AND GENE THERAPY MARKET SEGMENTATION

By Type

The global market can be segmented based on:

• Cell therapy: Transplanting cells into a patient in place of his damaged or diseased cells in a bid to treat him as a whole. This is executed in treatments like the CAR-T cell therapy.

• Gene Therapy: An intervention in the genetic material of the cells of a patient in a way that either suppresses the development of a disease or directly cures it, such as the therapy through vectors that deliver active copies of a gene into a patient's cells.

• Others: It is a catch-all category for some of the newest, emerging therapies that might blur the two approaches, cell therapy and gene therapy, or take advantage of other new technologies such as RNA-based therapies.

By Application

On the basis of applications, the worldwide market is segmented into the following:

• Oncology: Targeted cell and gene therapies in the war against the different forms of the disease—a variety from very tailored immunotherapies to gene-modified cell therapy.

• Rare Diseases: Therapy aimed at some rare and mostly genetic origin diseases, for which the conventional therapies might not have any efficacy, like spinal muscular atrophy, hemophilia;

• Cardiovascular Diseases: The genetic elements behind heart diseases, like regenerative treatments, implying cure of the heart tissues;

• Others: This includes the treatment for a plethora of other diseases, including those related to neurological disorders, metabolic diseases, infectious diseases, etc.

DRIVING FACTORS

"Increasing Prevalence of Chronic and Genetic Diseases"

Rising prevalence of chronic and genetic diseases is one of the major Driving Factors for the global cell and gene therapy market. With raised diagnostic measures of cancer, cardiovascular diseases, rare disorders, and genetic abnormalities, the demand for newer treatments that are super efficient has been on the rise. Cell and gene therapies offer a possibility that such conditions could possibly be cured instead of just being managed by solving the root causes at a cell and genetic level. Such an endeavor toward new, efficacious treatment, in turn, increases the demand for new treatments within cell and gene therapies.

"Growth in Demand through Increased Funding to Biotech and Research"

The other major booster of Cell and Gene Therapy Market growth has been titanic rises in funding towards biotech and research. Much of the government, private investment, and pharma firms are increasingly attracting cell and gene therapy development with greater vigor, as it has the potential to change/transform the way treatment has been conducted. These investments drive technological innovation, pipeline growth for therapeutic candidates, and facilitate the commercialization of novel treatments. This is only expected to further speed up the rise in the cell and gene therapy market by making a strong financial investment in this research and development activity done in this space.

RESTRAINING FACTORS

"High Costs and Regulatory Challenges"

One of the most significant curbing factors for this global market of cell and gene therapies is the fact that such treatments come at very high costs. Therapy processes are very costly due to the high degree of complexity and resource usage that come with the development, manufacturing, and application processes underpinning cellular and genetic therapies. Besides, it is also hard to regulate the environment under which some of these new treatments fall, as all of them have to pass under stringent clinical trials, safety, and efficacy measurements. These could consequently limit accessibility and affordability of the cell and gene therapies and impinge growth of this market.

• • 

    Download Free sampleto learn more about this report.

•  

CELL AND GENE THERAPY MARKET REGIONAL INSIGHTS

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

"North America Leading the Market Due to Strong Research Infrastructure and High Adoption Rates"

North America leads the global cell and gene therapy market share boosted by the robust research infrastructure and high adoption rates and supportive regulatory environment in the region. It is also a huge and important market on its own; with a huge concentration of leading biotech companies and research organizations, it usually leads in the advance of innovations in cell and gene therapy. More importantly within the region, the strong culture of innovation is supported with government and private investment, making one of the most enabling ecosystems for the development and commercialization of next-generation therapies. In addition, the population is highly affected by chronic diseases, which leads to growing demand for improved methods of treatment in North America.

KEY INDUSTRY PLAYERS

"Leading Players Steering with Innovation and Strategic Collaborations"

The following are major market players in the cell and gene therapy market. These are leading companies with unique strategic alliances and good research and development potentials in trying to formulate therapeutic agents for multiple diseases. These companies also manage market leadership by providing diversified portfolios to offer remedies for a long list of diseases. Most of them have been working on technological upgradation, promoting clinical trials, and collaborating with other leading industry players and research institutions to remain ahead in the competition. Moreover, such companies are developing new treatment and increasing its capacity to cater this rising demand of cell and gene therapies.

List of Market Players Profiled

• Novartis AG (Switzerland)
• Gilead Sciences, Inc. (U.S)
• Bluebird Bio, Inc. (U.S)
• Sangamo Therapeutics (U.S)
• Spark Therapeutics (U.S)
• CRISPR Therapeutics (Switzerland)
• Celgene Corporation (U.S)
• Orchard Therapeutics (U.K)
• Editas Medicine (U.S)
• UniQure N.V. (Netherlands)

INDUSTRIAL DEVELOPMENT

March 2024: Novartis AG is increasing its manufacturing capacity for cell therapy with a new, state-of-the-art site based in the U.S. The site will boost the company's developing pipeline of CAR-T cell therapies and other advanced therapies in response to global demand. The investment is a testament to Novartis' commitment to sustained leadership in the cell and gene therapy market, assured through innovation and expansion in infrastructure.

Five Recent Developments (2023-2025)

• 2023: Bristol Myers Squibb received U.S. approval for Breyanzi to treat chronic lymphocytic leukemia and small lymphocytic lymphoma, expanding the application of CAR-T cell therapy in hematologic cancers.
• 2023: Vertex Pharmaceuticals and CRISPR Therapeutics secured U.S. approval for CASGEVY, the first CRISPR-based gene-editing therapy approved for treating sickle cell disease.
• 2024: Johnson & Johnson obtained U.S. approval for CARVYKTI in earlier-line treatment of relapsed multiple myeloma, expanding patient eligibility for CAR-T therapy.
• 2024: Novartis expanded manufacturing capacity for cell and gene therapies by enhancing advanced production infrastructure and digital manufacturing technologies to support increasing patient demand.
• 2025: Pfizer continued expanding its gene therapy manufacturing network by investing in advanced viral vector production technologies and process automation to improve scalability and supply reliability.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.